![](http://menstreaz-dev.s3.us-east-1.amazonaws.com/images/bf590fdc5fd253bfe2f5ee5538f26cf7.jpg)
Urinary tract infections (UTIs) are a persistent issue for many, particularly premenopausal women who experience them recurrently. A recent study conducted in India sought to explore a potentially groundbreaking solution: probiotics. Specifically, the research investigated whether oral and vaginal probiotics could reduce the recurrence of UTIs among women with a history of these infections.
Study Design: A Closer Look at the Approach
In a 4-month randomized controlled trial, 174 premenopausal women aged 18-45 were divided into four groups, each receiving different combinations of treatments:
- Group 1 (Placebo): Oral placebo + vaginal placebo
- Group 2: Oral probiotic + vaginal placebo
- Group 3: Oral placebo + vaginal probiotic
- Group 4: Oral probiotic + vaginal probiotic
The oral probiotic boasted 112.5 billion CFU of lactic acid bacteria and Bifidobacteria, while the vaginal probiotic contained 1 billion CFUs of three Lactobacillus strains. The oral probiotic was administered daily, and the vaginal probiotic was used for eight consecutive days each month.
The Findings: Implications for UTI Management
Results at the 4-month mark showed that groups receiving any form of probiotic (Groups 2, 3, and 4) experienced fewer symptomatic UTI recurrences compared to the placebo group (Group 1). This trend was particularly pronounced by the 12-month follow-up, with Groups 3 and 4 showing significantly lower recurrence rates than Group 1. Group 2 did not maintain its early success, aligning more closely with the placebo group's outcomes at the year mark.
Interestingly, there was no significant difference in recurrence rates between Groups 3 and 4, suggesting that the addition of an oral probiotic may not enhance the efficacy of the vaginal probiotic in this context.
Duration Before Recurrence
Another critical aspect of the study was assessing the time to the first recurrence of a UTI. Both Group 3 and Group 4 participants enjoyed a significantly longer period before experiencing their first UTI post-treatment compared to those in Group 1 and Group 2. This indicates that the probiotic treatments not only reduced the frequency of infections but also delayed their onset.
Conclusion: A Forward Path with Probiotics
This study illuminates the potential of probiotics, particularly vaginal ones, as a preventative measure for recurrent UTIs in premenopausal women. While further research is needed to explore the mechanisms and long-term outcomes, the current findings offer hope for those seeking alternative preventative measures against this common and often frustrating condition.
Probiotics might soon be considered a staple in the preventive healthcare toolkit for women prone to recurrent UTIs, providing a natural and effective way to maintain urinary health.
- Gupta V, Mastromarino P, Garg R. Effectiveness of Prophylactic Oral and/or Vaginal Probiotic Supplementation in the Prevention of Recurrent Urinary Tract Infections: A Randomized, Double-Blind, Placebo-Controlled Trial. Clin Infect Dis. 2024 May 15;78(5):1154-1161. doi: 10.1093/cid/ciad766. PMID: 38084984.
- Koradia P, Kapadia S, Trivedi Y, Chanchu G, Harper A. Probiotic and cranberry supplementation for preventing recurrent uncomplicated urinary tract infections in premenopausal women: a controlled pilot study. Expert Rev Anti Infect Ther. 2019 Sep;17(9):733-740. doi: 10.1080/14787210.2019.1664287. Epub 2019 Sep 13. Erratum in: Expert Rev Anti Infect Ther. 2019 Nov;17(11):939. doi: 10.1080/14787210.2019.1673041. PMID: 31516055.
- Gupta V, Nag D, Garg P. Recurrent urinary tract infections in women: How promising is the use of probiotics? Indian J Med Microbiol. 2017 Jul-Sep;35(3):347-354. doi: 10.4103/ijmm.IJMM_16_292. PMID: 29063878.
- Stapleton AE, Au-Yeung M, Hooton TM, Fredricks DN, Roberts PL, Czaja CA, Yarova-Yarovaya Y, Fiedler T, Cox M, Stamm WE. Randomized, placebo-controlled phase 2 trial of a Lactobacillus crispatus probiotic given intravaginally for prevention of recurrent urinary tract infection. Clin Infect Dis. 2011 May;52(10):1212-7. doi: 10.1093/cid/cir183. Epub 2011 Apr 14. PMID: 21498386; PMCID: PMC3079401.
- Daniel M, Szymanik-Grzelak H, Turczyn A, Pańczyk-Tomaszewska M. Lactobacillus rhamnosus PL1 and Lactobacillus plantarum PM1 versus placebo as a prophylaxis for recurrence urinary tract infections in children: a study protocol for a randomised controlled trial. BMC Urol. 2020 Oct 23;20(1):168. doi: 10.1186/s12894-020-00723-1. PMID: 33097017; PMCID: PMC7583233.
- Abdullatif VA, Sur RL, Eshaghian E, Gaura KA, Goldman B, Panchatsharam PK, Williams NJ, Abbott JE. Efficacy of Probiotics as Prophylaxis for Urinary Tract Infections in Premenopausal Women: A Systematic Review and Meta-Analysis. Cureus. 2021 Oct 17;13(10):e18843. doi: 10.7759/cureus.18843. PMID: 34671514; PMCID: PMC8523083.